Skip to main content
. 2014 Mar 14;7(6):2023–2028. doi: 10.3892/ol.2014.1972

Figure 2.

Figure 2

Casticin preferentially inhibits proliferation and self-renewal of LCSCs derived from the MHCC97 cell line. (A) Casticin preferentially inhibited proliferation of CD133+ SFCs of the MHCC97 cell line. (B) SFCs were incubated with various concentrations of casticin (0.1, 0.5 and 1.0 Mmol/l) or DMSO for six days. (C) In the absence of casticin, the number of secondary tumorspheres derived from primary tumorspheres decreased compared with the control. Data are expressed as the mean ± standard deviation (n=3). *P<0.05 compared with treatment with the corresponding 0.1% dimethyl sulfoxide treatment group; #P<0.05 compared with the parental cells treated with corresponding concentration of casticin. LCSCs, liver cancer stem cells; CD133, cluster of differentiation 133; SFCs, sphere-forming cells.